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Advances in nanotechnology have demonstrated potential application of nanoparticles (NPs) for effective and
targeted drug delivery. Here we investigated the antimicrobial and immunological properties and the feasibility of
using NPs to deliver antimicrobial agents to treat a cutaneous pathogen. NPs synthesized with chitosan and
alginate demonstrated a direct antimicrobial activity in vitro against Propionibacterium acnes, the bacterium
linked to the pathogenesis of acne. By electron microscopy (EM) imaging, chitosan–alginate NPs were found to
induce the disruption of the P. acnes cell membrane, providing a mechanism for the bactericidal effect. The
chitosan–alginate NPs also exhibited anti-inflammatory properties as they inhibited P. acnes-induced inflamma-
tory cytokine production in human monocytes and keratinocytes. Furthermore, benzoyl peroxide (BP), a
commonly used antiacne drug, was effectively encapsulated in the chitosan–alginate NPs and demonstrated
superior antimicrobial activity against P. acnes compared with BP alone while demonstrating less toxicity to
eukaryotic cells. Together, these data suggest the potential utility of topical delivery of chitosan–alginate NP-
encapsulated drug therapy for the treatment of dermatologic conditions with infectious and inflammatory
components.
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INTRODUCTION
Nanoparticles (NPs) are currently being investigated and used
in many areas of medicine to allow for specific drug delivery,
lower dosing of active agents, combination therapy, minimize
side effects, and harness more potent drugs, which cannot
clinically be utilized by conventional drug delivery. In response
to the growing threat of microbial drug resistance, nanotech-
nology has become a major area of interest because of its many
unique characteristics. In particular, the physical and chemical
properties of NPs, including their high surface-to-volume ratio
and small size, allows for the ability to surpass barriers and gain
access to biological molecules and, importantly, microorgan-
isms (Blecher et al., 2011). This direct interaction with
microbial cell membranes/walls and key proteins/enzymes
can both inhibit pathogen growth and/or instigate cell death
through mechanisms different from our armament of antibiotics,
to which resistance has developed. In addition, the size, shape,
and chemical characteristics of NPs may be manipulated to
facilitate these molecular interactions, optimizing their ultimate
action (Kim et al., 2010; Blecher et al., 2011).
It has become apparent that the development of nanotech-
nology for the treatment of infectious diseases, particularly
skin disease, involves two major areas: the first utilizes
materials that at the nanoscale have inherent antimicrobial
properties (Hemmila et al., 2010), and the second incor-
porates known therapeutics into nano-vehicles to enhance
delivery and improve efficacy (Cunha-Azevedo et al., 2011;
Dominguez-Delgado et al., 2011; Kumar et al., 2011). The
ideal approach to develop a topical therapy for microbial
infection in skin would utilize a nanomaterial that has both
inherent and potent antimicrobial properties and the ability to
serve as a nano-vehicle would be ideal.
Chitosan is a natural polysaccharide biopolymer derived
from chitin, the principal structural component of the crusta-
cean exoskeleton. Depending on the degree of deacetylation,
chitosan can have an extensive collection of C2 amino groups,
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having pKa values of B6.5, which can become protonated in
weakly acidic conditions. It is this polycationic character that
confers chitosan’s antimicrobial properties, which favors
interaction with negatively charged microbial cell walls and
cytoplasmic membranes. These interactions result in
decreased osmotic stability, membrane disruption, and even-
tual leakage of intracellular elements (Ma et al., 2008; Sanpui
et al., 2008; Banergee et al., 2010). In addition, chitosan may
enter the nuclei of bacteria and fungi and inhibit mRNA and
protein synthesis by binding to microbial DNA (Qi et al.,
2005; Ma et al., 2008; Blecher et al., 2011). When
nanoscaled, chitosan has a higher surface-to-volume ratio,
translating into higher surface charge density, increased
affinity to bacteria and fungi, and greater antimicrobial
activity (Qi et al., 2005).
Even more so, chitosan possesses some immunological
functions including inhibition of proinflammatory cytokines,
promotion of tissue granulation through fibroblast recruitment
(Ueno et al., 2001), and production of type III collagen (Ueno
et al., 1999). Together, these data suggest that chitosan can be
utilized as an antimicrobial, anti-inflammatory, and wound
healing accelerant. However, although gaining a polycationic
charge in a weakly acidic environment, such as the one
supported by the epidermis, chitosan is weakly soluble in
physiological solvents, therefore limiting its clinical use to date
(Chavez de Paz et al., 2011).
Given the antimicrobial and immunological properties of
chitosan, we investigated whether chitosan–alginate NPs
could be effectively generated, stored, and delivered in phy-
siological parameters, demonstrate antimicrobial and anti-
inflammatory activity against a clinically important cutaneous
bacterium, Propionibacterium acnes, and whether these NPs
might be a useful approach to target acne therapy.
RESULTS
Antimicrobial activity of chitosan–alginate NPs
The primary goals of acne treatment are resolution of
inflammatory lesions, prevention of future comedo formation,
and prevention of persistent inflammation (Lee, 2009).
Therefore, for acne therapy, agents with both antimicrobial
and anti-inflammatory properties are highly effective. As
chitosan has demonstrated antimicrobial activity against
various pathogens, including Staphylococcus aureus (Jia
et al., 2001; Qi et al., 2005) and E. coli (Chen et al., 2002;
Sanpui et al., 2008), chitosan–alginate NPs were evaluated for
their antimicrobial activity against a common cutaneous
bacterium, P. acnes.
To synthesize nontoxic, biodegradable, and biocompatible
NPs that can be used for the treatment of cutaneous infections,
we chose a derivative of the biostructural crustacean shell
polymer chitin, chitosan, along with the well-known thermally
stable gelling agent, alginate (Sayag et al., 1996). The synthesis
of the chitosan–alginate NPs was demonstrated to be
successful using transmission electron microscopy (TEM)
visualization, which showed that the majority of individual
NPs were o50 nm in diameter (Figure 1a). Using dynamic
light scattering, particles were found to have an average
hydrodynamic diameter of 341.6±11.1 nm (Figure 1b) with
a polydispersity of 23.7. This is not surprising as measurements
are taken in water and chitosan NPs have been shown to
swell rapidly in this setting (Gelfuso et al., 2011; Jayakumar
et al., 2011).
To measure the antimicrobial activity against P. acnes, we
incubated the bacteria with varying doses of chitosan–alginate
NPs, as well as with chitosan and alginate control alone for
4 hours. Subsequently, the bacteria were plated and the
viability was determined by colony-forming unit (CFU) assay.
The chitosan–alginate NPs were effective at inhibiting the
growth of P. acnes in a dose-dependent manner and by
approximately four logs at the most concentrated dose of
NPs tested (Figure 2). We also demonstrated that chitosan
alone could inhibit the growth of P. acnes by a 5.0 log
decrease, but alginate had no effect on the growth of P. acnes.
These data demonstrate that chitosan–alginate NPs have
antimicrobial activity against P. acnes, and that the antimi-
crobial activity of the NPs was because of chitosan and not
alginate.
Anti-inflammatory effects of the chitosan–alginate NPs
As chitosan has been shown to have various anti-inflammatory
properties (Kim et al., 2004), we specifically investigated
whether the inflammatory cytokines and chemokines
induced by P. acnes could be modulated in the presence of
20
a
b
15
10
%
 In
te
ns
ity
5
0
1 10 100
Diameter (nm)
1,000
50 nm
Figure 1. Synthesis of chitosan–alginate nanoparticles. Nanoparticles were
synthesized using chitosan and alginate. The structure was analyzed using (a)
transmission electron microscopy (TEM; bar¼ 50 nm) and (b) analytical sizing
performed using dynamic light scattering (DLS).
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chitosan–alginate NPs. Human monocytes were isolated from
peripheral blood and stimulated cells with P. acnes in the
presence of various concentrations of chitosan–alginate NPs.
As shown in Figure 3a, P. acnes induction of cytokine IL-
12p40, previously shown to be involved in the inflammatory
response in acne, was inhibited by chitosan–alginate NPs in a
dose-dependent manner, demonstrating almost complete
reduction of IL-12 protein at the highest concentration of
chitosan–alginate NPs tested. Similarly, human keratinocyte
HaCaT cells were cultured and stimulated with P. acnes in the
presence of various concentrations of chitosan–alginate NPs.
We found that the induction of IL-6 by P. acnes in keratino-
cytes was inhibited in the presence of chitosan–alginate NPs
almost completely, even at a low-dose concentration
(Figure 3c). Chitosan–alginate NPs did not have a toxic effect
on human monocytes as demonstrated in the MTT assay
(Figure 3b), whereas sodium chromate, a positive control, had
a significant cytotoxic effect on human monocytes. On the
other hand, there was mild toxicity to HaCaT cells at
higher concentrations of NPs; however, when compared with
subclinical concentrations of benzoyl peroxide (BP), this
impact was insignificant (Figure 3d). Therefore, our data
suggest that chitosan–alginate NPs can inhibit P. acnes–
induced cytokine production in human monocytes and kera-
tinocyte, and this is not simply because of the release of
cytokines at cell death.
Chitosan–alginate NPs as a delivery vehicle for topical
therapeutics
Although chitosan alone shows antimicrobial activity against
P. acnes, the use of chitosan–alginate NPs provides the benefit
of incorporating multi-therapeutics. BP has both a mild
keratolytic and a potent bactericidal effect to which P. acnes
has yet to demonstrate resistance (Dutil, 2010). Although an
effective acne therapy, skin irritation is an expected
but an unwanted adverse event, and is frequent at
efficacious doses. Therefore, encapsulation in NPs could be
one approach of improving efficacy by reducing the side
effects associated with topical application and ultimately
improving patient compliance. In addition, BP and
chitosan together may provide superior antimicrobial effects
against P. acnes when combined in this format, each
providing a different mechanism of action. BP (0.1%) was
encapsulated into chitosan–alginate NPs and incubated
with P. acnes before plating and determination of bacterial
viability. The encapsulation of BP into NPs demonstrated
enhanced antimicrobial activity against P. acnes at
several concentrations tested (Figure 4a). The encapsulated
BP exhibited a synergistic antimicrobial activity against
P. acnes in comparison with NPs and BP alone at several
concentrations tested. Furthermore, the encapsulated
BP demonstrated less toxicity against eukaryotic cells than
BP alone (Figure 4b), suggesting that the encapsulation of BP
within the chitosan–alginate NPs may provide protection for
eukaryotic cells.
Chitosan–alginate NPs and NP-encapsulated BP induce cell wall
disruption of P. acnes
To determine the mechanism by which the chitosan–alginate
NP induces the killing of P. acnes, bacteria that were treated
with chitosan–alginate NPs were examined using both
scanning electron microscopy (SEM) and transmission
electron microscopy (TEM). The SEM photographs of untreated
P. acnes illustrated the bacterium’s normal structure demon-
strating the smooth and intact cell wall (Figure 5). A higher-
magnification TEM image revealed the normal cell wall
structure of P. acnes with well-demarcated outer and
inner dark lipophilic layers and a lighter hydrophilic pepti-
doglycan layer in the center. When the bacteria were
treated with chitosan–alginate NPs, the cell wall of P. acnes
appeared light, suggesting loss of lipids. Higher-magnification
TEM imaging demonstrated that the cell membranes
lost their lipophilic ‘‘sandwich-like’’ normal appearance. In
addition, the low TEM and SEM imaging revealed damage to
the cytoplasm.
The BP-treated bacteria also experienced some damage to
the cell wall and membrane. There was loss of the normal cell
wall structure and clustering of the membrane’s lipophilic
components into droplets with loss of normal cytoplasmic
features. However, the addition of NP-encapsulated BP to P.
acnes resulted in greater perturbation of the cell as compared
with native BP (0.1%). The TEM and SEM images revealed
severe disruption, destruction, and ‘‘peeling’’ of the cell wall.
Many cells appeared to have lost their cytoplasmic contents.
The lipophilic portion of the membrane showed alteration of
the structure and formation of relatively larger lipophilic
globules as well as a wider, edematous space within the cell
wall. These images suggest that the cell damage is due to an
osmotic disturbance.
1.0E+06
1.0E+07
1.0E+08
Control
Chitosan
NP
1.0E+01
1.0E+02
1.0E+03
1.0E+04
1.0E+05
1.0E+00
0 0.1 0.2 0.5 1
Ratio of stock
CF
U 
pe
r m
l
Figure 2. Antimicrobial effects of chitosan–alginate nanoparticles (NPs).
Various concentrations (1, 0.5, 0.2, and 0.1%) of chitosan–alginate NPs
were incubated with Propionibacterium acnes for 4 hours and tested for
antimicrobial activity using colony-forming unit (CFU) assay (mean CFU
per ml) and compared with chitosan and alginate as controls. These
data are derived from eight independent experiments±SEM (P-values:
wp0.005, zp0.001).
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DISCUSSION
In this paper, we synthesized chitosan–alginate NPs and
demonstrated that they are therapeutically multifaceted.
Chitosan–alginate NPs demonstrated potent antimicrobial
activity against P. acnes. Chitosan–alginate NPs were
shown to induce bacterial cell wall membrane disruption as
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Figure 3. Anti-inflammatory effects of chitosan–alginate nanoparticles (NPs). Chitosan–alginate NPs at various concentrations (6.5, 25, and 50% of stock,
respectively) were incubated with primary human monocytes or HaCaT cells, which were subsequently stimulated with Propionibacterium acnes. (a) IL-12p40 and
(c) IL-6 levels were determined by ELISA expressed by mean cytokine concentration (pg ml1) and are representative of four independent experiments±SEM
(P-values: **p0.01). (b, d) Cells were collected and evaluated for cell viability using (b) MTT and (d) MTS assays. Data are expressed by mean percentage as
compared with untreated cells and are composite of four independent experiments±SEM (for b, P-values: *p0.05, wp0.005, zp0.001; for d, P-values: *p0.05,
**p0.01, fp0.0001).
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Figure 4. Synergistic activity of benzoyl peroxide (BP)-encapsulated chitosan–alginate nanoparticles (NPs). (a) BP encapsulated into chitosan–alginate NPs
([BP 0.1%] NP) were incubated with Propionibacterium acnes for 4 hours and tested for antimicrobial activity using colony-forming unit (CFU) assay (mean CFU
per ml) and compared with chitosan–alginate NPs, BP 0.1%, and alginate as a negative control. These data are composite of eight distinct experiments±SEM
(P-values: **p0.01, wp0.005, zp0.001). (b) Primary human monocytes were stimulated with BP 0.1%, [BP 0.1%] NP, and Na2Cr2O7 as a positive control
for toxicity, and evaluated for cell viability using the MTT assay. Data are expressed by mean percentage as compared with untreated cells and are composite
of three independent experiments±SEM (P-value: zp0.001).
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demonstrated by electron microscopy (EM), suggesting a
mechanism for NP antimicrobial activity. The chitosan–
alginate NPs also exhibited anti-inflammatory properties, as
they inhibited P. acnes–induced inflammatory cytokine IL-12
production in human monocytes and IL-6 production in
human keratinocytes. Although chitosan alone exhibits potent
antimicrobial activity against P. acnes, its therapeutic
use can be challenging because of the solubility limitations
of native chitosan. The chitosan–alginate NP can therefore
overcome this limitation, yet still provide potent antimicrobial
activity and, furthermore, can be utilized as a delivery system
to incorporate additional therapeutics. Thus, the NP encapsu-
lation of BP, a common yet clinically irritating acne therapeutic,
resulted in an increased antimicrobial activity in comparison
with BP alone, while reducing toxicity to eukaryotic cells. Our
data suggest that the chitosan–alginate NPs may be useful for
the treatment of dermatologic conditions with infectious and
inflammatory components, such as acne vulgaris.
The treatment of cutaneous infections has been complicated
by the emergence of microbial species that are resistant to
standard antibiotic regimens (Spellberg, 2011; Spellberg et al.,
2011). This evolving medical challenge is of particular
significance in the treatment of one of the most common
cutaneous skin disease, acne vulgaris. The Gram-positive
bacteria P. acnes and, to a lesser extent, Propionibacterium
granulosum and Propionibacterium parvum are present and
contribute to acne lesions (Zaenglein and Thiboutot, 2003).
They produce enzymes and lipases that promote comedo
rupture, comedogenic and proinflammatory factors, and
glycocalyx polymers, which act as adhesives that cause
further aggregation of keratinocytes (Bellew et al., 2011). In
addition, P. acnes activates immune cells to produce
inflammatory mediators. Therefore, targeting both P. acnes
and its associated inflammation is key to optimal therapy. In
the setting of increasing resistance to standard antimicrobial
therapy, innovative antimicrobial agents and approaches are
needed (Kinney et al., 2010).
The NP platform described was formed by combining the
biostructural polymer chitosan with sodium alginate. Alginate
is a family of polysaccharides composed of a-L-guluronic acid
(G) and b-D-mannuronic acid (M) residues, arranged in
homopolymeric blocks of each type (MM, GG) and hetero-
polymeric blocks (MG). Alginates form strong complexes with
polycationic material, which stabilizes this gel-like material
SEM
P. acnes
P. acnes
+ NP
P. acnes
+ BP 0.1%
P. acnes
+ [BP 0.1%] NP
TEM (low power) TEM (high power)
Figure 5. Effects of chitosan–alginate nanoparticles (NPs), benzoyl peroxide (BP), and NP-encapsulated BP on the cell structure of Propionibacterium acnes.
Scanning electron microscopy (SEM; bar¼1mm), low-power transmission electron microscopy (TEM; bar¼ 1mm), and high-power TEM (bars¼ 100 nm)
demonstrated the effects of chitosan–alginate NP, BP alone (BP 0.1%), and NP-encapsulated BP ([BP 0.1%] NP) on P. acnes after 4 hours of incubation with the
bacteria. Electron microscopy (EM) studies represent data from at least three different experiments.
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and reduces its porosity. Among those polycations, chitosan
has received considerable attention because of its cationic
characteristics, as chitosan has the ability to gel on
contact with counter anions (Coppi et al., 2001; Coppi
and Iannuccelli, 2009). Chitosan’s amino groups are able to
interact with an anionic polymer that has carboxylic groups
such as alginate by ionic binding. Using EM, we demonstrated
that NPs measuring B50 nm in diameter were formed.
Interestingly, when suspended in water, the particles swell
to almost seven times their initial size, similarly witnessed by
previous investigators (Gelfuso et al., 2011; Luo et al., 2011;
Murugeshu et al., 2011). As chitosan is a hydrophilic polymer
that presents amine groups in its chemical structure, it can
form hydrogen bonds with water. Therefore, in the presence of
water, chitosan NPs can undergo swelling, forming a gel layer
around the particles because of chitosan hydration. This
swelling increases the diameter of these particles, likely
influencing the mechanism of drug release. For example, BP
can diffuse through the swollen particle. Therefore,
consideration must be given when translating this
technology to the vehicle in which these NPs are suspended
to effectively control the rate of swelling and therefore release
of therapeutics (Martinac et al., 2005).
Although the exact mechanism of how chitosan–alginate
NPs kill microbes is unclear, we demonstrated through TEM
and SEM the osmotic disruption of the P. acnes cell mem-
brane. Chitosan by itself is known to strongly adhere to
negatively charged surfaces because of its high-charge density
at pH o6.5. The interactions between the polycationic
chitosan and the electronegative charges on the cell surfaces
are thought to trigger perturbations in membrane integrity,
leading to alterations in cell permeability (Chen et al., 1998).
This interaction can lead to the leakage of intracellular
electrolytes and proteinaceous components. Many
endogenous cationic peptides, including granulysin, human
b-defensins, and cathelicidins, are thought to interact with the
negatively charged microbe cell wall to induce killing. The
advantage of using these molecules, which target conserved
membrane structures versus enzyme antagonists, is the low
possibility of microbe resistance, given the low probability
of a single mutation leading to altered bacterial membrane
structure. However, it has been shown that in certain
environments, S. aureus can express surface protein IsdA to
become less hydrophobic and thus resistant to skin innate
defenses (Clarke et al., 2007), underscoring the growing need
for new approaches to antimicrobial therapies.
Work by other investigators has shown that chitosan has
antimicrobial activities against various pathogens including
bacteria, fungi, and viruses, suggesting a broad antimicrobial
spectrum (Alburquenque et al., 2010; Tayel et al., 2010; El-
Sharif and Hussain, 2011; Jayakumar et al., 2011; Potara et al.,
2011). Despite distinctive differences between Gram-negative
and Gram-positive bacteria, the antibacterial agent’s first
interaction with its target will be at the cell surface,
compromising either the cell wall or outer membrane. For
Gram-positive bacteria, lipoteichoic acid could provide a
molecular linkage for chitosan at the cell surface, allowing it
to disturb membrane functions (Raafat et al., 2008).
Lipopolysaccharide and proteins in the Gram-negative
bacteria outer membrane are held together by electrostatic
interactions with divalent cations that are required for its
integrity and stabilization. Chitosan’s polycations may
compete with divalent metals for binding with polyanions
and has the potential to chelate important biologic metals
(Kong et al., 2008). Replacement of Mg2þ and Ca2þ ions
present in the cell wall likely disrupt the integrity of the cell
wall or influence the activity of degradative enzymes. These
data underscore the additional benefit of utilizing chitosan-
derived NPs for drug delivery.
The chitosan–alginate NPs were also found to have immu-
nomodulatory activity, inhibiting the production of inflamma-
tory cytokine IL-12p40 and IL-6 by P. acnes–stimulated
monocytes and keratinocytes, respectively. P. acnes is a potent
stimulator of host immune responses and because inflamma-
tion is a key pathogenic element of acne, it is tempting to
speculate that the anti-inflammatory activity of NPs is the
result of inhibition of the Toll-like receptor 2 pathway, given
the role of Toll-like receptor 2 activation in P. acnes–induced
cytokine and other proinflammatory mediators (Kim et al.,
2002; Jugeau et al., 2005; Nagy et al., 2005). Past studies have
provided insight into chitosan’s ability to inhibit inflammatory
cytokines and chemokines. It was shown that chitosan can
inhibit NF-kb activation in human mast cell lines through
downmodulation of Ca2þ -induced mast cell activation
(Seo et al., 2003) and suppression of mRNA expression of
membrane metalloproteinases 1 and 3 (Kim et al., 2004),
suggesting that chitosan interferes with the Toll-like receptor
signaling pathways. In addition, it has been shown that IL-6
can have a role as a regulator of extracellular matrix deposi-
tion through membrane metalloproteinases and is involved in
the immune response to P. acnes; as a consequence, it may be
an important determinant of acne and therefore downregula-
tion could be an important component of therapy (Pajulo
et al., 1999). The anti-inflammatory effects of chitosan–
alginate NPs suggest a possible role as immune modulating
agents that could be translated to clinical use in infectious and
other diseases with unwanted inflammatory reactions.
Because of chitosan’s polycationic nature as well as high
affinity to metal, it has been used as a carrier system and
platform stabilizer for a variety of NP systems, including
metallic NPs (Chadwick et al., 2010), nitric oxide–releasing
NPs (Friedman et al., 2008), and drug-containing NPs, which
allow for targeted delivery of various medications (Qi et al.,
2005). By combining this property with chitosan’s inherent
antimicrobial action, using chitosan as a delivery platform for
antimicrobial agents could potentially augment the anti-
microbial properties of these agents. For example, the
antimicrobial efficacy of silver-loaded membranes is
enhanced with increasing chitosan contents of up to 70%,
resulting in larger zones of inhibition against both S. aureus
and E. coli (Ma et al., 2008). Here we sought to encapsulate
and enhance the efficacy of BP, a common therapy used for
acne, in the chitosan–alginate NPs, as bacterial resistance
to BP has not been reported to date. We found that
nanoencapsulation of BP offers improved antimicrobial effi-
cacy at lower and, consequently, less irritating and toxic
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concentrations, suggesting that the chitosan–alginate NP
encapsulation of BP may offer a highly effective therapeutic
molecule with less irritation to the skin. In fact, the greatest
damage to P. acnes cell wall occurred with NP-encapsulated
BP. This is not surprising as BP exerts its influence through
oxidative stress and chitosan binds to the cellular membrane,
altering permeability and structural stability.
Given the multifaceted impact of the NPs, the presented
data inspire future in vivo studies to translate this technology
to clinical practice. Although future studies most certainly
include in vivo safety testing, such as clinical, histological,
and immunohistochemical evaluation following topical appli-
cation, the utility of studying efficacy in an animal model is
not clear, given the lack of established animal models.
Although rhino mouse model is occasionally used in the
literature, it only addresses hyperkeratotic effect of acne
pathogenesis and is typically not used for new therapeutic
development (Mirshahpanah and Maibach, 2007). Anti-
inflammatory in vivo models with P. acnes has been
reported (Fan et al., 2012); however, this model is also
limited in that it is an intradermal injection of P. acnes,
measuring a local, granulomatous, inflammatory response
rather than a true multifactorial acne model encompassing
the pilosebaceous unit. Finally, and from a translational
standpoint, the FDA (Food and Drug Administration) does
not require in vivo acne model for efficacy in the development
of therapeutics for acne, rather in vivo safety data are required
for preclinical safety data, which will be pursued as
mentioned above.
The known benefits of nano-drug delivery, including size,
stability, and encapsulation of a great range of therapeutics
(Mu and Sprando, 2010; Nasir, 2010; Schroeter et al., 2010),
combined with our data that chitosan–alginate NPs have both
antimicrobial and anti-inflammatory properties, suggest that
chitosan–alginate NPs have the potential to serve as a topical
class of antimicrobials for the treatment of acne vulgaris as
well as other cutaneous infections and inflammatory condi-
tions. Even more importantly, the combination of antimicro-
bial activities between chitosan and BP limits the risk of the
emergence of resistant species. Therefore, our findings suggest
that the chitosan–alginate NP encapsulation, which offers
enhanced antimicrobial and anti-inflammatory properties as
well as the promise of controlled release, provides previously
undescribed therapeutic opportunities, including delivery of
multidrug regimens to combat resistant microbes and inflam-
matory disease states.
MATERIALS AND METHODS
Production of NPs
A total of 70.0 mg of alginic acid sodium salt (Sigma Aldrich, St Louis,
MO) was added to 100 ml of dH2O (0.7 mg ml
 1) and magnetically
stirred until dissolved. Then, 15 mg of calcium chloride (CaCl2; Acros
Organics, Geel, Belgium) was stirred into 20 ml of dH2O
(0.75 mg ml 1). The 20 ml CaCl2 solution was added dropwise into
the alginic acid solution through a 27.5-gauge needle while the
alginic acid solution was concurrently sonicated. Following admin-
istration of CaCl2, sonication was maintained for 1 minute. The new
solution was stirred for 30 minutes. Following this, 7 mg of chitosan
(485% deacetylated, Sigma Aldrich), dissolved in 20 ml hydrochloric
acid (0.35 mg ml 1, pH 1.4–2.0; Fisher Scientific, Pittsburgh, PA),
was added dropwise through a 27.5-gauge needle into the alginic
acid–CaCl2 solution. The resulting mixture was stirred magnetically
for 1 hour and then allowed to settle over a 24-hour time period.
After 24 hours, the formed suspension was centrifuged at
4,000 r.p.m. for 1 hour. The supernatant was discarded with subse-
quent addition of 50 ml of dH2O. The suspension was again centri-
fuged at 4,000 r.p.m. for 1 hour and the past step was repeated twice.
Because of aggregation of particles, the suspension was extensively
vortexed for 2 minutes and then sonicated for 3.5 hours.
Encapsulation of BP
BP (0.1 g; Sigma Aldrich) was dissolved into 100 ml of 20% ethanol
(Sigma Aldrich) and spun for 1 hour. Then, 70.0 mg of alginic acid
was added to the mixture and spun to dissolve. Into 20 ml of ethanol
(0.75 mg ml 1), 1.5 mg of CaCl2 was stirred magnetically. The 20 ml
CaCl2 solution was added dropwise into the alginic acid solution
through a 27.5-gauge needle while the alginic acid solution was
concurrently being sonicated. Following the administration of CaCl2,
sonication was maintained for 1 minute. The new solution was stirred
for 30 minutes. Following this, 7 mg of chitosan dissolved in 20 ml
hydrochloric acid (0.35 mg ml 1, pH 1.4–2.0) was added dropwise
through a 27.5-gauge needle into the alginic acid–CaCl2 solution. The
resulting mixture was stirred for 1 hour and then allowed to settle over
a 24 hour period. After 24 hours, the now formed suspension was
centrifuged at 4,000 r.p.m. for 1 hour. The supernatant was discarded
and 50 ml of dH2O was added. The suspension was again centrifuged
at 4,000 r.p.m. for 1 hour and the past step was repeated twice.
Because of the aggregation of particles, the suspension was vortexed
for 2 minutes and then sonicated for 3.5 hours.
CFU assay
P. acnes strain ATCC 6919 (American Type Cell Culture, Manassas,
VA) was grown under anaerobic conditions in Reinforced Clostridial
Medium (Oxoid, Basingstroke, UK) for 3 days and collected in mid-
log phase. The bacteria were washed three times, suspended in
10 mM sodium phosphate, pH 7.2, supplemented with 0.03% trypti-
case soy broth (Becton-Dickinson, Cockeysville, MD), and enumer-
ated by applying a conversion factor of 7.5 107 bacteria per ml¼ 1
OD unit at 600 nm (Beckman DU 640B Spectrophotometer,
Beckman Coulter, Fullerton, CA). Various concentrations of alginate,
chitosan, and chitosan–alginate NPs (1%, 0.5%, 0.2% and 0.1%)
were incubated with 3.75 105 bacteria in a final volume of 30ml at
37 1C for 4 hours. After incubation, 10-fold dilutions were prepared
and plated onto Brucella Agar supplemented with 5% sheep blood,
hemin, and vitamin K (Remel, Lenexa, KS). Plates were incubated for
4 days at 37 1C under anaerobic conditions. Individual colonies were
counted and the number of CFU was tabulated.
Electron microscopy
P. acnes at a concentration of 2.08 107 bacteria per ml was
suspended in 10 mM sodium phosphate buffer, pH 7.2, supplemented
with 0.03% trypticase soy broth, and incubated with chitosan–
alginate NPs, BP 0.1%, [BP 0.1%] NP, and alginate as a control.
Samples were then fixed for 30 minutes with 2% gluteraldehyde in
1 phosphate-buffered saline, pH 7.35, at room temperature,
washed three times, and suspended in 1 ml of 1 phosphate-
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buffered saline. The SEM samples were filtered onto a micropore
filter. The filters with the sample on top were dehydrated in graded
ethanol: 50, 75, 95, and 100% for 15 minutes in each, followed by
similar transfers in hexa-methyl-disilazane reagent: 50, 75, and 95%
for 30 minutes each followed by 100% hexa-methyl-disilazane
reagent overnight. The SEM samples were gold coated, and then
viewed and photographed on a Cambridge Scanning electron micro-
scope (Cambridge Instruments, Cambridge, UK). TEM samples were
dehydrated in graded ethanol as above, embedded in Epon, and
sectioned on Sorvall MT6000 (RMC, Tucson, AZ). Thin sections
(75mm) were stained with uranyl acetate, viewed, and photographed
on Jeol XC100 (JEOL, Tokyo, Japan) at 80 kV.
Dynamic light scattering
A dilute suspension of chitosan–alginate particles (0.1 mg ml 1) was
sonicated and then the size of the particles was measured using
dynamic light scattering. The dynamic light scattering measurement
was performed using DynaPro NanoStar (Wyatt Technology, Santa
Barbara, CA), using an acquisition length of 5 seconds and a total
of 40 acquisition attempts. An average particle hydrodynamic
diameter (the diameter of the particle along with the shell of closely
associated water molecules) and polydispersity was calculated from
the results.
Primary human monocyte isolation and stimulation
Peripheral human blood was drawn from normal healthy volunteers
into heparinized tubes according to a protocol approved by the
institutional review board at University of California, Los Angeles,
and gathered according to the Declaration of Helsinki Principles.
Written consent was received before blood draw and use of material.
Peripheral blood mononuclear cells were then isolated using Ficoll-
Paque gradients (Amersham Biosciences, Piscataway, NJ) and plated
(5 106 per well) in 24-well plates with RPMI media (Invitrogen,
Grand Island, NY) containing 1% fetal calf serum (FCS; Omega
Scientific, Tarzana, CA) for 2 hours at 37 1C. Nonadherent cells were
removed by washing three times with RPMI media. Adherent
monocytes were cultured in RPMI containing 10% FCS and left
untreated or incubated with alginate, chitosan, and chitosan–alginate
NPs for 1 hour before the addition of P. acnes sonicate (1mg ml 1) for
24 hours at 37 1C. Supernatants were harvested 24 hours later and
assayed for IL-12p40 by ELISA (BD Pharmingen, San Diego, CA).
Human keratinocyte cell line, HaCaT cells were cultured with
keratinocyte media containing 1% FCS (Omega Scientific). Cells
were cultured in RPMI containing 10% FCS and left untreated or
incubated with alginate, chitosan, and chitosan–alginate NPs for
1 hour before the addition of P. acnes sonicate (1mg ml 1) for
24 hours at 37 1C. Supernatants were harvested 24 hours later and
assayed for IL-6 by ELISA (BD Pharmingen).
MTT/MTS toxicity assay
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrasodium bro-
mide tetrazolium; Sigma Aldrich) is a yellow, water-soluble com-
pound processed by the mitochondria of live cells into a water-
insoluble purple formazan salt that can be measured at 570 nm. The
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) assay reagent is used to measure dehy-
drogenase enzyme activity found in metabolically active cells.
Peripheral blood mononuclear cells and HaCaT cells were isolated
as above and plated at 2 105 cells per well in a 96-well plate for
2 hours. Nonadherent cells were removed by washing twice with
RPMI. In addition, HaCaT keratinocytes were also plated for 2 hours.
Chitosan–alginate NPs, BP 0.1%, and [BP 0.1%] NP were prepared in
RPMI containing 10% FCS and 50ml of each compound was added to
the wells containing peripheral blood mononuclear cells. Chitosan–
alginate NPs and BP 0.1% were added to the wells containing HaCat.
All compounds were evaluated in triplicates, including a positive
control of sodium chromate (20–100mM) and media as the negative
control. The wells were incubated at 37 1C overnight. Within
24 hours, the wells were washed twice with 200ml of sterile 1
phosphate-buffered saline. For the MTT, 100ml of RPMI containing
10% MTT (5 mg ml 1) and 10% FCS were added to each well and
incubated for 4 hours. Without washing, 100ml of 10% SDS were
added to each well and incubated for 8 hours. Absorbance was
measured at 570 nm using a microplate reader. For the MTS, 20ml of
MTS assay reagent (Promega) was added to each well, and cells were
incubated for 4 hours at 37 1C. The absorbances were read at 490 nm,
with the number of viable cells absorbance proportional to absor-
bance. Treated wells were compared with the media control as
percent of untreated media.
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